10-Q: PROCEPT BioRobotics Reports Strong Q1 2025 Revenue Growth Driven by Increased System Sales and Utilization

PROCEPT BioRobotics Corporation announces a 55% increase in revenue for Q1 2025, driven by growth in system sales and utilization of Aquablation therapy.

Summary

• PROCEPT BioRobotics Corporation reported a revenue increase of 55% for the first quarter of 2025, reaching $69.2 million compared to $44.5 million in Q1 2024.
• The company's net loss decreased slightly to $24.7 million from $26.0 million in the same period last year.
• As of March 31, 2025, PROCEPT had $316.2 million in cash and cash equivalents and an accumulated deficit of $570.7 million.
• The company's install base grew to 703 AquaBeam and HYDROS Robotic Systems globally, with 547 in the United States.
• Gross margin improved to 64% in Q1 2025 from 56% in Q1 2024, attributed to higher sales volumes and increased average selling prices.
• The company is focused on expanding its install base, increasing system utilization, and securing favorable reimbursement coverage.
• PROCEPT believes its existing cash and cash equivalents, along with anticipated revenue, will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and improved gross margins, although the company is still operating at a loss. The company's confidence in its ability to fund operations for the next twelve months is also a positive sign.

Positives

• Significant revenue growth driven by increased system sales and utilization.
• Improved gross margin due to higher sales volumes and increased average selling prices.
• Growing install base of robotic systems globally.
• Positive Medicare coverage determinations have been a catalyst for hospital adoption.
• The company achieved the twelve-month revenue target as of December 31, 2024, extending the interest-only period on its term loan facility.

Negatives

• The company continues to operate at a net loss, although the loss has decreased slightly year-over-year.
• The company has an accumulated deficit of $570.7 million.
• Operating expenses, particularly selling, general, and administrative expenses, are increasing as the company expands its commercial infrastructure.

Risks

• The company's future performance depends on market acceptance of its products and Aquablation therapy.
• Reimbursement and coverage decisions by third-party payors can significantly impact revenue.
• The company faces risks related to manufacturing costs and supply chain management.
• The company's future growth depends on continuous improvements and innovation, which require significant resources and investment.
• Changes in United States trade policy, including the imposition of tariffs, may have a material adverse impact on the business and results of operations.

Future Outlook

The company anticipates continued revenue growth and believes its existing cash and cash equivalents, along with anticipated revenue, will be sufficient to fund operations for at least the next twelve months.

Management Comments

• The company is focused on driving adoption of Aquablation therapy and increasing system utilization.
• The company plans to leverage treatment data and software development capabilities to integrate artificial intelligence and machine learning.

Industry Context

PROCEPT BioRobotics operates in the surgical robotics market, specifically targeting urology with a focus on treating benign prostatic hyperplasia (BPH). The company's Aquablation therapy represents a paradigm shift in the surgical treatment of BPH by addressing compromises associated with alternative surgical interventions.

Comparison to Industry Standards

• The WATER study, PROCEPT's U.S. pivotal trial, is the only FDA pivotal study randomized against transurethral resection of prostate (TURP), the historical standard of care for BPH.
• The company's technology aims to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms (LUTS) due to BPH, independent of prostate size and shape, and delivers resection independent of surgeon experience.
• The company has established strong relationships with key opinion leaders, or KOLs, within the urology community and collaborated with key urological societies in global markets.

Legal Proceedings

• From time to time, the Company may be involved in legal proceedings arising in the ordinary course of our business.
• The Company is not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on the business.

Stakeholder Impact

• Shareholders: The company's strong revenue growth and improved gross margins are positive signs for shareholders.
• Employees: The company's expansion and growth plans may create new job opportunities.
• Customers: The company's focus on innovation and continuous improvement may lead to better products and services for customers.
• Suppliers: The company's increased production volumes may lead to increased demand for suppliers' products and services.

Next Steps

• The company plans to continue expanding its install base of robotic systems.
• The company plans to increase system utilization.
• The company plans to secure favorable reimbursement coverage from third-party payors.
• The company plans to continue investing in research and development to drive continuous improvements and innovation.

Key Dates

Keywords

Aquablation, Robotics, BPH, Urology, Revenue, PROCEPT, Financial Results, Medical Devices